NewAmsterdam Pharma (NASDAQ:NAMS) Insider Johannes Jacob Piete Kastelein Sells 94,124 Shares of Stock

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) insider Johannes Jacob Piete Kastelein sold 94,124 shares of the company’s stock in a transaction that occurred on Friday, March 6th. The stock was sold at an average price of $30.32, for a total transaction of $2,853,839.68. Following the transaction, the insider owned 69,302 shares in the company, valued at $2,101,236.64. The trade was a 57.59% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link.

Johannes Jacob Piete Kastelein also recently made the following trade(s):

• On Monday, March 9th, Johannes Jacob Piete Kastelein sold 101,409 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $30.29, for a total transaction of $3,071,678.61.
• On Thursday, March 5th, Johannes Jacob Piete Kastelein sold 104,467 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $30.30, for a total transaction of $3,165,350.10.
• On Friday, February 20th, Johannes Jacob Piete Kastelein sold 45,481 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $35.31, for a total transaction of $1,605,934.11.
• On Monday, January 5th, Johannes Jacob Piete Kastelein sold 6,000 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $33.25, for a total value of $199,500.00.

NewAmsterdam Pharma Stock Performance

Shares of NAMS opened at $30.77 on Tuesday. The business’s fifty day moving average price is $33.48 and its two-hundred day moving average price is $33.32. The firm has a market capitalization of $3.54 billion, a price-to-earnings ratio of -17.79 and a beta of 0.04. NewAmsterdam Pharma Company N.V. has a 52 week low of $14.06 and a 52 week high of $42.00.

NewAmsterdam Pharma (NASDAQ:NAMS) last released its earnings results on Wednesday, February 18th. The company reported ($0.63) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.23). NewAmsterdam Pharma had a negative return on equity of 26.67% and a negative net margin of 906.22%.The firm had revenue of $0.03 million for the quarter, compared to the consensus estimate of $0.92 million. As a group, research analysts forecast that NewAmsterdam Pharma Company N.V. will post -1.75 EPS for the current year.

Analyst Upgrades and Downgrades

NAMS has been the topic of a number of research reports. Needham & Company LLC upped their target price on shares of NewAmsterdam Pharma from $46.00 to $48.00 and gave the company a “buy” rating in a research report on Wednesday, February 18th. The Goldman Sachs Group lifted their price target on shares of NewAmsterdam Pharma from $30.00 to $37.00 and gave the stock a “neutral” rating in a research report on Tuesday, December 2nd. Leerink Partners reissued an “outperform” rating and set a $55.00 price target on shares of NewAmsterdam Pharma in a research note on Tuesday, January 6th. Royal Bank Of Canada increased their price objective on shares of NewAmsterdam Pharma from $44.00 to $47.00 and gave the company an “outperform” rating in a report on Wednesday, January 21st. Finally, HC Wainwright raised shares of NewAmsterdam Pharma to a “strong-buy” rating in a report on Thursday, February 19th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, NewAmsterdam Pharma currently has an average rating of “Moderate Buy” and a consensus target price of $47.10.

Hedge Funds Weigh In On NewAmsterdam Pharma

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Wells Fargo & Company MN grew its position in shares of NewAmsterdam Pharma by 50.0% during the 4th quarter. Wells Fargo & Company MN now owns 900 shares of the company’s stock worth $32,000 after buying an additional 300 shares during the period. Geode Capital Management LLC raised its position in shares of NewAmsterdam Pharma by 0.4% in the 4th quarter. Geode Capital Management LLC now owns 102,395 shares of the company’s stock valued at $3,590,000 after acquiring an additional 437 shares during the period. Arizona State Retirement System raised its position in shares of NewAmsterdam Pharma by 3.8% in the 3rd quarter. Arizona State Retirement System now owns 13,251 shares of the company’s stock valued at $377,000 after acquiring an additional 483 shares during the period. China Universal Asset Management Co. Ltd. boosted its stake in NewAmsterdam Pharma by 2.4% during the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 22,549 shares of the company’s stock worth $408,000 after acquiring an additional 521 shares during the last quarter. Finally, The Manufacturers Life Insurance Company boosted its stake in NewAmsterdam Pharma by 5.3% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 10,868 shares of the company’s stock worth $197,000 after acquiring an additional 544 shares during the last quarter. Institutional investors own 89.89% of the company’s stock.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.